BioLife Secures U.S. Patent for First-of-its-kind Effervescent Oral Peptide Delivery Technology
10 سبتمبر 2026 - 14:00
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910717829/en/
BioLife offers a new solution for oral GLP-1 delivery
The announcement comes as demand for GLP-1 medicines continues to accelerate. GLP-1 therapies generated approximately $132 billion in global sales in 2025, while obesity medicines now represent an estimated $42 billion market. 1 As more patients seek alternatives to injections, demand for alternative oral treatments continues to grow.
First generation oral GLP-1 medicines have demonstrated the value of oral administration while also underscoring on the fundamental challenges in peptide drug development: protecting large peptide molecules as they move through the gastrointestinal tract.
BioLife’s unique technology was developed to explore what comes next. Built on more than 35 years of pharmaceutical effervescence expertise, this novel approach to oral peptide delivery uses a dissolvable effervescent tablet format that creates a first-of-its-kind gastric buffer designed to help protect peptide therapeutics through the digestive system and support their absorption.
"GLP-1 medicines have changed how obesity and metabolic disease are treated, but we still need better oral options," said Dr. Farid Bennis, Founder of BioLife and inventor of the technology known internally as OralMatrix. "This patent represents much more than protection for a formulation. It reflects decades of scientific work focused on addressing on the most important challenges in peptide medicine: helping these molecules pass through the digestive system intact, for today’s therapies and for future generations of peptide therapeutics."
The technology takes a different approach to oral peptide drug delivery. Rather than relying on special coatings or absorption-enhancing ingredients, it uses a dissolvable effervescent format designed to help protect peptide medicines as they move through the digestive system.
Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration, providing in vivo proof of concept for the approach. The granted U.S. claims extend across the GLP-1 class, including semaglutide, liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. Patent protection runs into 2042 with additional patent applications pending internationally.
Oral peptide drug delivery remains an important area of innovation as pharmaceutical companies evaluate increasingly sophisticated therapies for obesity, diabetes and metabolic disease. The opportunity extends beyond today's GLP-1 medicines and toward future generations of peptide therapeutics.
About the Technology
BioLife’s patented effervescent peptide delivery technology uses a dissolvable tablet format designed to support oral delivery of peptide medicines, including GLP-1 therapies. Preclinical studies have demonstrated measurable systemic semaglutide exposure following oral administration.
The development programme builds on nearly 20 years of research, including human clinical studies with oral insulin formulations and collaborations with Charles River Laboratories, SGS, Eurofins/Amatsi and Cephac.
The technology is in development and is not approved for the treatment of any disease.
About Dr. Farid Bennis
Dr. Farid Bennis, eminent expert in effervescence research and technology is the founder of BioLife, named inventor on U.S. Patent No. 12,667,605 B2, and Chairman of the pharmaceutical company Laprophan Group, established in 1949 and present in more than 40 countries.
Over more than 35 years, Dr Bennis has developed pharmaceutical effervescence technologies across multiple therapeutic areas, resulting in numerous patented inventions and commercialized healthcare products. The technology reflects nearly two decades of work devoted to oral peptide delivery.
About BioLife
BioLife develops oral delivery technologies for peptide medicines, combining expertise in pharmaceutical effervescence, formulation science and oral peptide research.
The company's technology portfolio and related patent estate have been independently developed and are wholly owned.
Sources
1 Managed Healthcare Executive, "GLP-1 Drugs to Drive Growth in Obesity and Diabetes Treatment," reporting IQVIA market data presented at AMCP Annual 2026. Available at: https://www.managedhealthcareexecutive.com/view/glp-1-drugs-to-drive-growth-in-obesity-and-diabetes-treatment-amcp-annual-2026
View source version on businesswire.com: https://www.businesswire.com/news/home/20260910717829/en/
Contact
Media & Partner Enquiries
US: Peter Opitz
608-712-9614
Europe: Misha Talheth-Fells
+447548907984
Business & Licensing: Paul Sagan
617-852-0495
LaVoie Strategic Communications Group, Inc.
© 2026 Business Wire, Inc.
BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.
Disclaimer:
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.